Sir, The recent paper by Wilmshurst et al. 1 concluded that the beneficial haemodynamic effects of amrinone in patients with left ventricular impairment were attributable to vasodilatation, the drug having no demonstrable positive inotropic properties. This conclusion-which is at variance with a considerable body of experimental and clinical data-was based on the failure of amrinone to influence indices of left ventricular contractility. In two previous clinical studies, however, significant increments in left ventricular dp/dt max in excess of 40% were observed after amrinone therapy.23 Wilmshurstet al. proposed that simultaneous increments in heart rate were sufficient to account for this finding, apparently ignoring the fact that a similar increase in heart rate during their own study was associated with no change at all in left ventricular dp/dt max. Moreover, the paper by Benotti et al.2 reported pronounced increments in left ventricular dp/dt max even in patients in whom heart rate remained unchanged.
Thus, the apparent absence of a positive inotropic response to amrinone in the patients studied by Wilmshurst et al. demands an alternative explanation which probably relates to the design of their study. When haemodynamic measurements are made directly after routine coronary angiography a stable baseline-ssential in studies of this type-cannot be guaranteed. Atropine premedication, for example, ensures a changing vagal influence during the period of investigation.
Of added concern is the large though unspecified quantity of contrast material these patients must have received during the coronary and (duplicate) left ventricular angiograms. The In our paper7 we stated that "at least part of the increase in max dp/dt is the result of the increase in heart rate" not that "the increments in heart rate were sufficient to account for this" as stated by Timmis 5 also performed cineangiography at the time of their study in six patients but they do not say when.
The use of angiography does present problems, but the combination of diagnostic and research procedures makes this necessary. The alternative is two separate catheterisations. We were initially worried about giving an "inotropic" agent to patients with coronary artery disease and so elected to perform coronary angiography first. We used biplane cineangiography and the minimum number of injections (five to six injections, 5 to 8 ml 76% Urografin). The interval between coronary angiography and the subsequent research procedure always exceeded 45 minutes. We do not believe this is contrary to standard practice. As we stated7 the interval between the first left ventricular cineangiogram and subsequent interventions/measurements exceeded 20 minutes and no measurements were made after the second left ventricular cineangiogram. Our study was a haemodynamic study and 20 minutes after angiography is adequate for return to haemodynamic baseline, as Timmis et al. point out. The metabolic effects of contrast are of some relevance. Unlike the majority of our patients, all those in the series by Wisneski et al. 8 had coronary artery disease, and in these the metabolic effects of angiography are exaggerated."1 In the paper by Wisneski et al. 8 at 20 minutes after left ventricular cineangiography all the metabolic effects were of small and decreasing magnitude, with the exception of arterial concentration and myocardial extraction of free fatty acid. We feel that the time of heparinisation may be in part responsible for the reduction in arterial free fatty acid at 20 minutes. 12 We find it interesttng that in this paper8 10 
